Chapter 23 Pharmacoeconomic Calculations Ellen S. Campbell, Ph.D. Associate Professor Division of...
-
Upload
gregory-suarez -
Category
Documents
-
view
221 -
download
0
Transcript of Chapter 23 Pharmacoeconomic Calculations Ellen S. Campbell, Ph.D. Associate Professor Division of...
![Page 1: Chapter 23 Pharmacoeconomic Calculations Ellen S. Campbell, Ph.D. Associate Professor Division of Economic, Social & Administrative Pharmacy.](https://reader035.fdocuments.us/reader035/viewer/2022062307/551b4773550346dd1a8b59f8/html5/thumbnails/1.jpg)
Chapter 23Pharmacoeconomic Calculations
Ellen S. Campbell, Ph.D.Associate ProfessorDivision of Economic, Social & Administrative Pharmacy
![Page 2: Chapter 23 Pharmacoeconomic Calculations Ellen S. Campbell, Ph.D. Associate Professor Division of Economic, Social & Administrative Pharmacy.](https://reader035.fdocuments.us/reader035/viewer/2022062307/551b4773550346dd1a8b59f8/html5/thumbnails/2.jpg)
OutlineCase StudyPharmacoeconomics definedPE Analyses Steps Perspectives Alternatives Examples of 4 types Sensitivity analysis Discounting
Pricing Issues
![Page 3: Chapter 23 Pharmacoeconomic Calculations Ellen S. Campbell, Ph.D. Associate Professor Division of Economic, Social & Administrative Pharmacy.](https://reader035.fdocuments.us/reader035/viewer/2022062307/551b4773550346dd1a8b59f8/html5/thumbnails/3.jpg)
Case Study background
• Bob is director of pharmacy for a large MCO where he manages all aspects of the health plan’s pharmacy budget.
• The health plan has more than 300,000 members
• Last year more than $78 million was spent for pharmaceuticals.
• This was 20% higher than the previous year
![Page 4: Chapter 23 Pharmacoeconomic Calculations Ellen S. Campbell, Ph.D. Associate Professor Division of Economic, Social & Administrative Pharmacy.](https://reader035.fdocuments.us/reader035/viewer/2022062307/551b4773550346dd1a8b59f8/html5/thumbnails/4.jpg)
Case Study problem
• a new sulfonylurea has been approved by the FDA.
• The product is similar to products on the market and is approved for the treatment of type II diabetes.
• Drug representatives have pointed out that it has a more favorable side effect profile than products currently on the market
• It is priced 20% higher than the current medications used by the MCO.
![Page 5: Chapter 23 Pharmacoeconomic Calculations Ellen S. Campbell, Ph.D. Associate Professor Division of Economic, Social & Administrative Pharmacy.](https://reader035.fdocuments.us/reader035/viewer/2022062307/551b4773550346dd1a8b59f8/html5/thumbnails/5.jpg)
Question
Does Bob request that the P&T committee add the new drug to the formulary? If so, at what tier?
![Page 6: Chapter 23 Pharmacoeconomic Calculations Ellen S. Campbell, Ph.D. Associate Professor Division of Economic, Social & Administrative Pharmacy.](https://reader035.fdocuments.us/reader035/viewer/2022062307/551b4773550346dd1a8b59f8/html5/thumbnails/6.jpg)
What is …
MCO P&T committee Formularytier
![Page 7: Chapter 23 Pharmacoeconomic Calculations Ellen S. Campbell, Ph.D. Associate Professor Division of Economic, Social & Administrative Pharmacy.](https://reader035.fdocuments.us/reader035/viewer/2022062307/551b4773550346dd1a8b59f8/html5/thumbnails/7.jpg)
What information would you use to answer the question?
Does Bob request that the P&T committee add the new drug to the formulary?
![Page 8: Chapter 23 Pharmacoeconomic Calculations Ellen S. Campbell, Ph.D. Associate Professor Division of Economic, Social & Administrative Pharmacy.](https://reader035.fdocuments.us/reader035/viewer/2022062307/551b4773550346dd1a8b59f8/html5/thumbnails/8.jpg)
Answer
Adopt a new drug or treatment if…
the additional benefit is higher than the additional cost
(global economic principle)
![Page 9: Chapter 23 Pharmacoeconomic Calculations Ellen S. Campbell, Ph.D. Associate Professor Division of Economic, Social & Administrative Pharmacy.](https://reader035.fdocuments.us/reader035/viewer/2022062307/551b4773550346dd1a8b59f8/html5/thumbnails/9.jpg)
Health Outcomes
What are the consequences of a particular treatment?
![Page 10: Chapter 23 Pharmacoeconomic Calculations Ellen S. Campbell, Ph.D. Associate Professor Division of Economic, Social & Administrative Pharmacy.](https://reader035.fdocuments.us/reader035/viewer/2022062307/551b4773550346dd1a8b59f8/html5/thumbnails/10.jpg)
Pharmacoeconomics is
a set of methods that evaluate theEconomic, Clinical and Humanistic Outcomes
(ECHO Model) of pharmaceutical products and
services…
![Page 11: Chapter 23 Pharmacoeconomic Calculations Ellen S. Campbell, Ph.D. Associate Professor Division of Economic, Social & Administrative Pharmacy.](https://reader035.fdocuments.us/reader035/viewer/2022062307/551b4773550346dd1a8b59f8/html5/thumbnails/11.jpg)
Pharmacoeconomics is
to compare the economic resources consumed (inputs) to produce the health and economic consequences of products or services (outcomes).
INPUTS OUTCOMES
Economic Health and Economic Resources Consequences
![Page 12: Chapter 23 Pharmacoeconomic Calculations Ellen S. Campbell, Ph.D. Associate Professor Division of Economic, Social & Administrative Pharmacy.](https://reader035.fdocuments.us/reader035/viewer/2022062307/551b4773550346dd1a8b59f8/html5/thumbnails/12.jpg)
Four types of Pharmacoeconomic Analyses
1. Cost-minimization (CMA)2. Cost-benefit (CBA)3. Cost-effectiveness (CEA)4. Cost-utility (CUA)
![Page 13: Chapter 23 Pharmacoeconomic Calculations Ellen S. Campbell, Ph.D. Associate Professor Division of Economic, Social & Administrative Pharmacy.](https://reader035.fdocuments.us/reader035/viewer/2022062307/551b4773550346dd1a8b59f8/html5/thumbnails/13.jpg)
Comparison of PE Methods
Method Cost Consequences
Cost Minimization Dollars Natural units(show
equivalency)
Cost Effectiveness Dollars Natural units
Cost Benefit Dollars Dollars
Cost Utility Dollars QALYs
![Page 14: Chapter 23 Pharmacoeconomic Calculations Ellen S. Campbell, Ph.D. Associate Professor Division of Economic, Social & Administrative Pharmacy.](https://reader035.fdocuments.us/reader035/viewer/2022062307/551b4773550346dd1a8b59f8/html5/thumbnails/14.jpg)
Steps for conducting a PE Analysis
1. define the problem2. identify the perspective and
alternative interventions to be compared
3. identify and measure outcomes of each alternative
4. identify, measure and value costs of all alternatives
5. use discounting and sensitivity analysis when appropriate
![Page 15: Chapter 23 Pharmacoeconomic Calculations Ellen S. Campbell, Ph.D. Associate Professor Division of Economic, Social & Administrative Pharmacy.](https://reader035.fdocuments.us/reader035/viewer/2022062307/551b4773550346dd1a8b59f8/html5/thumbnails/15.jpg)
Define the problem and state the objective
What is the most cost effective treatment of type II diabetes?
![Page 16: Chapter 23 Pharmacoeconomic Calculations Ellen S. Campbell, Ph.D. Associate Professor Division of Economic, Social & Administrative Pharmacy.](https://reader035.fdocuments.us/reader035/viewer/2022062307/551b4773550346dd1a8b59f8/html5/thumbnails/16.jpg)
Identify the perspective…
that is, who will be utilizing the information to make what decisions.This will guide you in choosing the relevant costs and benefits.
![Page 17: Chapter 23 Pharmacoeconomic Calculations Ellen S. Campbell, Ph.D. Associate Professor Division of Economic, Social & Administrative Pharmacy.](https://reader035.fdocuments.us/reader035/viewer/2022062307/551b4773550346dd1a8b59f8/html5/thumbnails/17.jpg)
Different Perspectives
Perspective Relevant: Costs Consequences
Patient OOP costs, lost income, transportation
Therapeutic effectiveness,Adverse events, QOL
MCO Hospitalization,Pharmacy, Personnel,& supplies
Therapeutic effectiveness,Adverse events
Third-Party Payers
Hospitalization, Pharmacy, Nursing home care
None
Society All possible costs including lost productivity
All possible consequences including QOL, & life years.
![Page 18: Chapter 23 Pharmacoeconomic Calculations Ellen S. Campbell, Ph.D. Associate Professor Division of Economic, Social & Administrative Pharmacy.](https://reader035.fdocuments.us/reader035/viewer/2022062307/551b4773550346dd1a8b59f8/html5/thumbnails/18.jpg)
Identify Alternative Interventions
What are the relevant choices?Often a head-to-head comparison of the most used (traditional) treatment with the new one.It’s important to compare with the most likely substitute for a realistic result.The comparator doesn’t have to be a drug therapy.
![Page 19: Chapter 23 Pharmacoeconomic Calculations Ellen S. Campbell, Ph.D. Associate Professor Division of Economic, Social & Administrative Pharmacy.](https://reader035.fdocuments.us/reader035/viewer/2022062307/551b4773550346dd1a8b59f8/html5/thumbnails/19.jpg)
At least two comparators
1. New sulfonylurea Versus
2. Most commonly used drug
![Page 20: Chapter 23 Pharmacoeconomic Calculations Ellen S. Campbell, Ph.D. Associate Professor Division of Economic, Social & Administrative Pharmacy.](https://reader035.fdocuments.us/reader035/viewer/2022062307/551b4773550346dd1a8b59f8/html5/thumbnails/20.jpg)
Cost and Effectiveness Comparison Grid for Drug 1 vs Drug 2
Effectiveness
Cost
1 > 2 1 = 2 1 < 2
1 > 2 Analyze Choose 2 Choose 2
1 = 2 Choose 1Indifferent
Choose 2
1 < 2 Choose 1 Choose 1 Analyze
![Page 21: Chapter 23 Pharmacoeconomic Calculations Ellen S. Campbell, Ph.D. Associate Professor Division of Economic, Social & Administrative Pharmacy.](https://reader035.fdocuments.us/reader035/viewer/2022062307/551b4773550346dd1a8b59f8/html5/thumbnails/21.jpg)
Identify and measure outcomes of each intervention (natural units or $)
Typical outcomes include: cured of illness improved quality of life decreased incidence of morbidity extended life relief or reduction in symptoms Adverse events (drug interactions and
side-effects) mortality
![Page 22: Chapter 23 Pharmacoeconomic Calculations Ellen S. Campbell, Ph.D. Associate Professor Division of Economic, Social & Administrative Pharmacy.](https://reader035.fdocuments.us/reader035/viewer/2022062307/551b4773550346dd1a8b59f8/html5/thumbnails/22.jpg)
Identify, Measure and Value costs
Costs include:direct medical costs like treatment costs, direct non-medical costs like transportation,indirect costs like missed work,intangible costs like pain.
Be sure to include those costs that are relevant to your perspective.
![Page 23: Chapter 23 Pharmacoeconomic Calculations Ellen S. Campbell, Ph.D. Associate Professor Division of Economic, Social & Administrative Pharmacy.](https://reader035.fdocuments.us/reader035/viewer/2022062307/551b4773550346dd1a8b59f8/html5/thumbnails/23.jpg)
Measuring Costs over time
Costs are measured over a relevant time period such as a month or year. The length used depends on the typical span of the illness of interest.
Analysis of acute disease such as the flu would have a short span; while chronic or long-term illness such as depression or heart disease would span years.
![Page 24: Chapter 23 Pharmacoeconomic Calculations Ellen S. Campbell, Ph.D. Associate Professor Division of Economic, Social & Administrative Pharmacy.](https://reader035.fdocuments.us/reader035/viewer/2022062307/551b4773550346dd1a8b59f8/html5/thumbnails/24.jpg)
1. Cost-Minimization Analysis (CMA)
This type of evaluation compares two or more alternative treatments that are clinically equivalent in terms of outcomes or consequences. Once equivalency is demonstrated, the focus is on choosing the one with the smallest total costs.Example – generic versus name brand
![Page 25: Chapter 23 Pharmacoeconomic Calculations Ellen S. Campbell, Ph.D. Associate Professor Division of Economic, Social & Administrative Pharmacy.](https://reader035.fdocuments.us/reader035/viewer/2022062307/551b4773550346dd1a8b59f8/html5/thumbnails/25.jpg)
Calculating cost differentials between therapeutic agents
Drug A is administered via 100 mg tablet orally, twice a day, for 30 days. Each 100 mg tablet costs $7.50Drug B requires three weekly IV administrations with increasing dosages as follows: (dose 1) 250,000 IU (dose 2) 500,000 IU (dose 3) 750,000 IU Cost of Drug B is $68 per 250,000 IU and
administration is $25 per dose
![Page 26: Chapter 23 Pharmacoeconomic Calculations Ellen S. Campbell, Ph.D. Associate Professor Division of Economic, Social & Administrative Pharmacy.](https://reader035.fdocuments.us/reader035/viewer/2022062307/551b4773550346dd1a8b59f8/html5/thumbnails/26.jpg)
Cost differential (or incremental cost) for entire regimenTotal cost of Drug A = 30 days x 2 x $7.50 = $450Total cost of Drug B = drug cost + adm Dose 1 = (1 x 68) + 25 = 93 Dose 2 = (2 x 68) + 25 = 161 Dose 3 = (3 x 68) + 25 = 229 = $483
Cost differential is 483 – 450 = $33Incremental cost of changing from Drug A to Drug B is $33
![Page 27: Chapter 23 Pharmacoeconomic Calculations Ellen S. Campbell, Ph.D. Associate Professor Division of Economic, Social & Administrative Pharmacy.](https://reader035.fdocuments.us/reader035/viewer/2022062307/551b4773550346dd1a8b59f8/html5/thumbnails/27.jpg)
Cost differentials for chronic diseases are calculated on
Per patient per dayPer patient per month (30 days)
Why?
![Page 28: Chapter 23 Pharmacoeconomic Calculations Ellen S. Campbell, Ph.D. Associate Professor Division of Economic, Social & Administrative Pharmacy.](https://reader035.fdocuments.us/reader035/viewer/2022062307/551b4773550346dd1a8b59f8/html5/thumbnails/28.jpg)
Different outcome?
Using Cost Minimization Analysis (CMA) is only appropriate if the outcomes are shown to be equivalent.If not – must use alternative technique to account for the differenced in outcomes
![Page 29: Chapter 23 Pharmacoeconomic Calculations Ellen S. Campbell, Ph.D. Associate Professor Division of Economic, Social & Administrative Pharmacy.](https://reader035.fdocuments.us/reader035/viewer/2022062307/551b4773550346dd1a8b59f8/html5/thumbnails/29.jpg)
2. Cost-effectiveness Analysis (CEA)
If you can measure the therapeutic effect in “natural units” (I.e. weight gained, blood cholesterol level reduction) you compare the Cost per gain in therapeutic effect. Choose the smallest.Cost-Effectiveness Ratio =
Cost ($) Therapeutic effect (Natural units)
![Page 30: Chapter 23 Pharmacoeconomic Calculations Ellen S. Campbell, Ph.D. Associate Professor Division of Economic, Social & Administrative Pharmacy.](https://reader035.fdocuments.us/reader035/viewer/2022062307/551b4773550346dd1a8b59f8/html5/thumbnails/30.jpg)
Two ratio calculations for CEA
Cost-Effectiveness Ratio = Cost ($)
Therapeutic effect (Natural units)
Incremental Cost-Effectiveness Ratio = cost differential ($) outcome differential (Natural units)
![Page 31: Chapter 23 Pharmacoeconomic Calculations Ellen S. Campbell, Ph.D. Associate Professor Division of Economic, Social & Administrative Pharmacy.](https://reader035.fdocuments.us/reader035/viewer/2022062307/551b4773550346dd1a8b59f8/html5/thumbnails/31.jpg)
Cost-effectiveness Example
In this example, effectiveness is mg of glucose lowered. Could also measure effectiveness as cure rate as in the textbook example.
Cost Effectiveness
Avg. C/E Ratio
IncrementalC/E Ratio
Drug A $50 30 mg/dl
Drug B $70 40 mg/dl
![Page 32: Chapter 23 Pharmacoeconomic Calculations Ellen S. Campbell, Ph.D. Associate Professor Division of Economic, Social & Administrative Pharmacy.](https://reader035.fdocuments.us/reader035/viewer/2022062307/551b4773550346dd1a8b59f8/html5/thumbnails/32.jpg)
Cost-effectiveness Example
In this example, effectiveness is mg of glucose lowered. Could also measure effectiveness as cure rate as in the textbook example.
Cost Effectiveness
Avg. C/E Ratio
IncrementalC/E Ratio
Drug A $50 30 mg/dl 50/30
Drug B $70 40 mg/dl 70/40(70-50)/(40-30)
![Page 33: Chapter 23 Pharmacoeconomic Calculations Ellen S. Campbell, Ph.D. Associate Professor Division of Economic, Social & Administrative Pharmacy.](https://reader035.fdocuments.us/reader035/viewer/2022062307/551b4773550346dd1a8b59f8/html5/thumbnails/33.jpg)
Cost-effectiveness Example
In this example, effectiveness is mg of glucose lowered. Could also measure effectiveness as cure rate as in the textbook example.
Cost Effectiveness
Avg. C/E Ratio
IncrementalC/E Ratio
Drug A $50 30 mg/dl$1.67per mg/dl
Drug B $70 40 mg/dl$1.75per mg/dl
$2 per additional mg/dl
![Page 34: Chapter 23 Pharmacoeconomic Calculations Ellen S. Campbell, Ph.D. Associate Professor Division of Economic, Social & Administrative Pharmacy.](https://reader035.fdocuments.us/reader035/viewer/2022062307/551b4773550346dd1a8b59f8/html5/thumbnails/34.jpg)
3. Cost-Benefit Analysis (CBA)
When all costs and benefits of alternative actions are expressed in dollars. There are two ways to express the results:
1. Calculate the Benefit to Cost ratio for each action
Benefit ($) Cost ($)
Gives you the value gained per dollar spent (>1)2. Or calculate the Net Benefit
= Benefit ($) – Cost ($) Gives you the net gain (loss) from the action
![Page 35: Chapter 23 Pharmacoeconomic Calculations Ellen S. Campbell, Ph.D. Associate Professor Division of Economic, Social & Administrative Pharmacy.](https://reader035.fdocuments.us/reader035/viewer/2022062307/551b4773550346dd1a8b59f8/html5/thumbnails/35.jpg)
Example of Cost-Benefit Analysis
Four therapies are used to control hyperglycemia.
Per patient Per day
A B C D
Cost 5.88 4.96 4.08 3.78
Benefit 53.75 53.75 43.85
33.42
Net Benefit 47.87 48.79 39.77
29.64
Benefit/Cost Ratio
9.14 10.84 10.74
8.84
![Page 36: Chapter 23 Pharmacoeconomic Calculations Ellen S. Campbell, Ph.D. Associate Professor Division of Economic, Social & Administrative Pharmacy.](https://reader035.fdocuments.us/reader035/viewer/2022062307/551b4773550346dd1a8b59f8/html5/thumbnails/36.jpg)
4. Cost-Utility Analysis (CUA)
Similar to Cost-Effectiveness, this type of evaluation measures cost per gain in utility derived from the intervention. Utility is a measure how happy, healthy or satisfied someone is. The scale varies. Common examples are 0 – 1 or 0 – 10 or 0 - 100
![Page 37: Chapter 23 Pharmacoeconomic Calculations Ellen S. Campbell, Ph.D. Associate Professor Division of Economic, Social & Administrative Pharmacy.](https://reader035.fdocuments.us/reader035/viewer/2022062307/551b4773550346dd1a8b59f8/html5/thumbnails/37.jpg)
Quality-Adjusted Life Years
Utility is often combined with a measure of life expectancy to obtain quality-adjusted life years (QALYs).One healthy QALY = 1.0 is one year in perfect healthDeath QALY = 0.0
Example: 3 years of life as disabled (rated at utility 0.5) = 1.5 QALYs
![Page 38: Chapter 23 Pharmacoeconomic Calculations Ellen S. Campbell, Ph.D. Associate Professor Division of Economic, Social & Administrative Pharmacy.](https://reader035.fdocuments.us/reader035/viewer/2022062307/551b4773550346dd1a8b59f8/html5/thumbnails/38.jpg)
Two ratio calculations for CUA
Cost-Utility Ratio = Cost ($)
QALYs
Incremental Cost-Utility Ratio = cost differential ($) outcome differential (QALYs)
![Page 39: Chapter 23 Pharmacoeconomic Calculations Ellen S. Campbell, Ph.D. Associate Professor Division of Economic, Social & Administrative Pharmacy.](https://reader035.fdocuments.us/reader035/viewer/2022062307/551b4773550346dd1a8b59f8/html5/thumbnails/39.jpg)
Cost-Utility example
Surgery vs Surgery plus chemotherapy
Treatment
Cost life year
s
Utility
(0-1)
QALY
CU Ratio
Incremental CU ratio
Surgery14000 3 .8 2.4
$5833 per
QALY
Surgery + chemo
27000 5 .6 3.0$9000
per QALY
$21,667 per QALY
![Page 40: Chapter 23 Pharmacoeconomic Calculations Ellen S. Campbell, Ph.D. Associate Professor Division of Economic, Social & Administrative Pharmacy.](https://reader035.fdocuments.us/reader035/viewer/2022062307/551b4773550346dd1a8b59f8/html5/thumbnails/40.jpg)
Cost-Utility
Pro: This is the only measure that includes patient quality information.
Con: There is a lack of standardization in utility measurement ( I.e. subjective).
![Page 41: Chapter 23 Pharmacoeconomic Calculations Ellen S. Campbell, Ph.D. Associate Professor Division of Economic, Social & Administrative Pharmacy.](https://reader035.fdocuments.us/reader035/viewer/2022062307/551b4773550346dd1a8b59f8/html5/thumbnails/41.jpg)
Sensitivity Analysis
When estimating costs and outcomes, you typically have a range of possible values. Sensitivity analysis requires that the results be recalculated at the different values to see if the conclusions change.
![Page 42: Chapter 23 Pharmacoeconomic Calculations Ellen S. Campbell, Ph.D. Associate Professor Division of Economic, Social & Administrative Pharmacy.](https://reader035.fdocuments.us/reader035/viewer/2022062307/551b4773550346dd1a8b59f8/html5/thumbnails/42.jpg)
Sensitivity analysis of Cost-Utility example
Surgery vs Surgery plus chemotherapy
Treatment
Cost life year
s
Utility
QALY
range
CU Ratio
Incremental CU ratio
Surgery14000 2 - 4 .8
1.63.2
$8,750$4,375
Surgery + chemo
27000 4 - 6 .62.43.6
$11,250
$7,500
no gain - $6,500 per
QALY
![Page 43: Chapter 23 Pharmacoeconomic Calculations Ellen S. Campbell, Ph.D. Associate Professor Division of Economic, Social & Administrative Pharmacy.](https://reader035.fdocuments.us/reader035/viewer/2022062307/551b4773550346dd1a8b59f8/html5/thumbnails/43.jpg)
Discounting
If the analysis spans more than a year, then the dollar values must be adjusted to a common time.Discounting adjusts future costs or benefits using an expected interest or discount rate.Present Value = Future value
(1+r)n
where r = discount rate (.03 - .06 is typical)and n = the number of years in the future.
![Page 44: Chapter 23 Pharmacoeconomic Calculations Ellen S. Campbell, Ph.D. Associate Professor Division of Economic, Social & Administrative Pharmacy.](https://reader035.fdocuments.us/reader035/viewer/2022062307/551b4773550346dd1a8b59f8/html5/thumbnails/44.jpg)
Discounting example
You wish to implement a diabetes DSM program which will cost you $1500 per year. The benefits from this program won’t be evident for 2 years, so you want to evaluate it after 4 years. Use r = .05 (i.e. 5%)
Year Costs PV
this year
1,500 1,500
1 1,500 1,429
2 1,500 1,361
3 1,500 1,296
total
$6,000
$5,586
![Page 45: Chapter 23 Pharmacoeconomic Calculations Ellen S. Campbell, Ph.D. Associate Professor Division of Economic, Social & Administrative Pharmacy.](https://reader035.fdocuments.us/reader035/viewer/2022062307/551b4773550346dd1a8b59f8/html5/thumbnails/45.jpg)
Pharmaceutical PricingWhen trying to assess cost you need
to accurately reflect depending on the perspective.
Two issues impact drug price the pharmacy must pay
1. Patent2. Available substitutes
![Page 46: Chapter 23 Pharmacoeconomic Calculations Ellen S. Campbell, Ph.D. Associate Professor Division of Economic, Social & Administrative Pharmacy.](https://reader035.fdocuments.us/reader035/viewer/2022062307/551b4773550346dd1a8b59f8/html5/thumbnails/46.jpg)
Pricing concepts
Acquisition cost (AAC) for pharmacy is the trade price less discounts Quantity discounts Promotional discounts Advertising or display allowances
Average Wholesale price (AWP) is often used by third-party payers (insurers)
![Page 47: Chapter 23 Pharmacoeconomic Calculations Ellen S. Campbell, Ph.D. Associate Professor Division of Economic, Social & Administrative Pharmacy.](https://reader035.fdocuments.us/reader035/viewer/2022062307/551b4773550346dd1a8b59f8/html5/thumbnails/47.jpg)
Pricing conceptsSeries discounts occur when you have more than one discount applied to a product. You cannot simply add the discounts together to get the single discount equivalent. They are applied to an already discounted amount.To get a single discount equivalent, subtract each rate from 100% and multiply the percents. Subtract the result from 100% to get the single discount rate.
![Page 48: Chapter 23 Pharmacoeconomic Calculations Ellen S. Campbell, Ph.D. Associate Professor Division of Economic, Social & Administrative Pharmacy.](https://reader035.fdocuments.us/reader035/viewer/2022062307/551b4773550346dd1a8b59f8/html5/thumbnails/48.jpg)
Series discount example
Your business gets a standard trade discount of 25% from list price. Your order gets a 10% quantity discount. Finally, you get a 3% cash discount.
.75 x .90 x .97 = .655100% – 65.5% = 34.5% discount rate
![Page 49: Chapter 23 Pharmacoeconomic Calculations Ellen S. Campbell, Ph.D. Associate Professor Division of Economic, Social & Administrative Pharmacy.](https://reader035.fdocuments.us/reader035/viewer/2022062307/551b4773550346dd1a8b59f8/html5/thumbnails/49.jpg)
MarkupPercent over cost that is charged for a product (source of profit).
Example if your standard markup is 75%, then how much will you charge for a bottle of aspirin that costs you $1?
What is your profit on the sale of that aspirin?
![Page 50: Chapter 23 Pharmacoeconomic Calculations Ellen S. Campbell, Ph.D. Associate Professor Division of Economic, Social & Administrative Pharmacy.](https://reader035.fdocuments.us/reader035/viewer/2022062307/551b4773550346dd1a8b59f8/html5/thumbnails/50.jpg)
Pricing for prescriptions & pharmaceutical services
Generally a markup is added to cost of ingredients to get price charged.A dispensing or professional fee can also be added to obtain a final price. This fee is typically an average value of pharmacist services (wage x time spent) provided during a transaction. It should be independent of the cost of ingredients.
![Page 51: Chapter 23 Pharmacoeconomic Calculations Ellen S. Campbell, Ph.D. Associate Professor Division of Economic, Social & Administrative Pharmacy.](https://reader035.fdocuments.us/reader035/viewer/2022062307/551b4773550346dd1a8b59f8/html5/thumbnails/51.jpg)
Summary of Pharmacoeconomic issues1. Perspective2. Type of analysis3. Appropriate Comparators?4. Relevant costs and consequences5. Validated instruments6. Time period, discounting7. Sensitivity analysis8. Generalizability